INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,842 | +22.2% | 1,264 | +48.5% | 0.01% | -12.5% |
| Q2 2023 | $53,885 | +84.6% | 851 | +57.9% | 0.02% | +77.8% |
| Q1 2023 | $29,187 | +5.3% | 539 | +2.9% | 0.01% | 0.0% |
| Q4 2022 | $27,730 | +38.6% | 524 | +23.6% | 0.01% | -10.0% |
| Q3 2022 | $20,000 | -20.0% | 424 | -2.5% | 0.01% | -33.3% |
| Q2 2022 | $25,000 | -70.9% | 435 | -69.1% | 0.02% | -65.1% |
| Q1 2022 | $86,000 | – | 1,407 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |